子宫肉瘤中KIT蛋白表达：一项免疫组织化学研究及文献综述
KIT protein expression in uterine sarcomas: an immunohistochemical study and review of the literature.
作者信息
Zafrakas M, Theodoridis T D, Zepiridis L, Venizelos I D, Agorastos T, Bontis J
机构信息
1st Department of Obstetrics & Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece.
出版信息
Eur J Gynaecol Oncol. 2008;29(3):264-6.
PURPOSE
The aim of the present study was to investigate the possibility of treating uterine sarcomas with imatinib mesylate. Imatinib mesylate, a selective tyrosine kinase inhibitor, is very efficient against mesenchymal tumors of the gastrointestinal tract, known as GISTs. Imatinib mesylate acts against a tyrosine kinase encoded by the KIT gene in GISTs, and is more effective in tumors expressing this protein.
METHODS
Expression of KIT was analyzed immunohistochemically (n = 12) in formalin-fixed paraffin-embedded primary uterine sarcomas.
RESULTS
Using a semi-quantitative immunohistochemical score we found that KIT expression was very weak in the majority of tumors, while none of the uterine sarcomas tested showed strong expression. Overall, published studies addressing this issue in small series of uterine sarcomas yielded similar results.
CONCLUSION
Current data suggest that it is unlikely that imatinib mesylate could be used effectively as a single agent in patients with uterine sarcomas.
目的
本研究旨在探讨甲磺酸伊马替尼治疗子宫肉瘤的可能性。甲磺酸伊马替尼是一种选择性酪氨酸激酶抑制剂，对胃肠道间质瘤（GISTs）这种间充质肿瘤非常有效。甲磺酸伊马替尼作用于GISTs中由KIT基因编码的酪氨酸激酶，在表达该蛋白的肿瘤中更有效。
方法
对12例福尔马林固定石蜡包埋的原发性子宫肉瘤进行免疫组织化学分析KIT的表达。
结果
使用半定量免疫组织化学评分，我们发现大多数肿瘤中KIT表达非常弱，而所检测的子宫肉瘤均未显示强表达。总体而言，针对少量子宫肉瘤系列研究该问题的已发表研究得出了类似结果。
结论
目前的数据表明，甲磺酸伊马替尼不太可能作为单一药物有效地用于子宫肉瘤患者。
Zotero 插件